Published online Dec 28, 2021. doi: 10.13105/wjma.v9.i6.568
Peer-review started: August 7, 2021
First decision: October 2, 2021
Revised: October 8, 2021
Accepted: December 24, 2021
Article in press: December 24, 2021
Published online: December 28, 2021
Processing time: 142 Days and 16.6 Hours
Osteosarcoma is one of the most common primary malignant bone tumors in children, with rapid progress and poor prognosis. microRNA (miRNA) has been proposed as a valuable biomarker for the prognosis of osteosarcoma, but the results are not consistent.
We wished to gain a detailed insight into the effect of circulating miRNA on the prognosis of patients with osteosarcoma.
The aim of this meta-analysis was to study the prognostic value of miRNA expression in patients with osteosarcoma.
A literature search was conducted to identify studies published through July 1, 2021. Random-effects meta-analyses were conducted for combinations of the outcomes of overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival in osteosarcoma patients. Subgroup analyses were conducted to identify sources of heterogeneity. Publication bias was assessed by Egger’s bias indicator test.
A total of 60 studies were included for this meta-analysis. The pooled HR for OS, DFS, PFS were 2.92 (95%CI: 2.43-3.41, P = 0.000), 3.70 (95%CI: 2.80-4.61, P = 0.000), and 3.57 (95%CI: 1.60-5.54, P = 0.000), respectively. The high expression levels of miR-21 were associated with poor OS in osteosarcoma (HR = 2.86, 95%CI: 1.20-4.53, P = 0.001).
Circulating miRNA could be used as a potential prognostic biomarker for oste
Evidence from later studies could consolidate these conclusions. A large number of samples prospective studies are needed in the future to enhance the persuasiveness of our conclusion.